Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

about

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

Item

http://www.wikidata.org/entity/Q43686215

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@en

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@nl

type

Item

label

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@en

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@nl

prefLabel

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@en

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@nl

P1476

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

@en

P2093

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Harry de Koning

http://www.w3.org/2001/XMLSchema#string

Meelan Bul

http://www.w3.org/2001/XMLSchema#string

Monique J Roobol

http://www.w3.org/2001/XMLSchema#string

Pim J van Leeuwen

http://www.w3.org/2001/XMLSchema#string

Ries Kranse

http://www.w3.org/2001/XMLSchema#string

Suzie J Otto

http://www.w3.org/2001/XMLSchema#string

Xiaoye Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.

Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study.

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Estimates of the cancer incidence and mortality in Europe in 2006.

Tomatoes, lycopene, and prostate cancer: progress and promise.

Statin drugs and risk of advanced prostate cancer.

P304

188-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2011.10811.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221790329

http://www.w3.org/2001/XMLSchema#string

P698

22288823

http://www.w3.org/2001/XMLSchema#string